Chlorimipramine: a novel anticancer agent with a mitochondrial target
1Experimental Neuro-oncology Group, Department of Neuropathology, Institute of Psychiatry, King's College London, London SE5 8AF, UK.
Abstract:
Mitochondria have been suggested to be a potential intracellular target for cancer chemotherapy. In this report, we demonstrate the ability of the tricyclic antidepressant chlorimipramine to kill human glioma cells in vitro by a molecular mechanism resulting in an increase in caspase 3 activity following inhibition of glioma oxygen consumption. Studies with isolated rat mitochondria showed that chlorimipramine specifically inhibited mitochondrial complex III activity, which causes decreased mitochondrial membrane potential as well as mitochondrial swelling and vacuolation. The use of chlorimipramine in human as an effective, non-toxic cancer therapeutic having a strong selectivity between cancer cells and normal cells on the basis of their mitochondrial function is discussed.
Insights
The antidepressant chlorimipramine effectively kills human glioma cancer cells by targeting mitochondrial function. This mechanism involves inhibiting oxygen consumption and increasing caspase 3 activity, offering a selective cancer therapy approach.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Mitochondria play a crucial role in cellular metabolism and are implicated in cancer development.
- Targeting mitochondrial dysfunction presents a promising strategy for cancer chemotherapy.
Purpose of the Study:
- To investigate the potential of the tricyclic antidepressant chlorimipramine as a novel anti-cancer therapeutic.
- To elucidate the molecular mechanism by which chlorimipramine affects human glioma cells.
Main Methods:
- In vitro studies using human glioma cells.
- Analysis of mitochondrial function, including oxygen consumption and mitochondrial complex III activity.
- Assessment of caspase 3 activity and mitochondrial morphology.
Main Results:
- Chlorimipramine demonstrated potent cytotoxicity against human glioma cells in vitro.
- The drug specifically inhibited mitochondrial complex III activity, leading to decreased oxygen consumption.
- Increased caspase 3 activity and observable mitochondrial swelling and vacuolation were noted.
Conclusions:
- Chlorimipramine effectively targets glioma cells by disrupting mitochondrial function.
- The observed selectivity based on mitochondrial activity suggests potential for targeted cancer therapy.
- Further investigation into chlorimipramine as a non-toxic, selective anti-cancer agent is warranted.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Antidepressant Drugs: MAOIs and Other Agents
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Anthelminthic Agents


